Lessons from the BEAT trial: implications for inhaled treprostinil from a double-blind, randomized trial
Year: 2026
Type: article
Abstract: Background Combination therapy is recommended for pulmonary arterial hypertension (PAH), part of which generally includes prostanoids, which affect both the vascular tone and vessel remodeling seen in PAH. This study tested whether a dual prostacyclin treatment strategy (oral esuberaprost + inhaled treprostinil and oral background PAH therapies) would provide additional clinical benefit. Methods 271 World Health Organization functional class (FC) III/IV patients with PAH received placebo or 28.4 µg oral esuberaprost 4 times daily, in addition to newly initiated or ongoing inhaled treprostinil and background therapies. Results There was no difference between treatment groups in time to clinical worsening (primary endpoint); 49 (36.0%) patients on esuberaprost and 51 (37.8%) on placebo had a clinical worsening event. No favorable esuberaprost treatment effects were observed for the secondary or exploratory endpoints (6-minute walk distance [6MWD], Borg dyspnea score, and N-terminal pro-brain natriuretic peptide [NT-proBNP]). There were 21 all-cause deaths attributable to clinical worsening (esuberaprost: 8 [5.9%]; placebo: 13 [9.6%]). Post hoc exploratory analyses to investigate the effect of inhaled treprostinil on treprostinil-naïve patients ( n = 151) found that the addition of inhaled treprostinil was associated with improvements in multiple components of risk status, NT-proBNP, and 6MWD from screening through week 52, irrespective of background therapy. Notably, similar improvements were observed in patients on dual background therapy. Conclusion While the study did not meet its primary endpoint, the post hoc findings were consistent with current guideline recommendations to use multidimensional risk assessment when evaluating treatment response in PAH. Trial registration Beraprost-314d Added-on to Tyvaso ® (BEAT) NCT01908699; Registered 2013-07-26 https://clinicaltrials.gov/study/NCT01908699.
Source: BMC Pulmonary Medicine
Authors: Mordechai R Kramer, Sonja Bartolome, Rajan Saggar, Robert C Bourge, H James Ford, Boris Medarov, Jeffrey S Sager, Shelly M Shapiro, Aaron B Waxman, David Ishizawar, Ronald J Oudiz, Jordan Shin, Prakash Sista, Michael DiMarino, Aimee Smart, Mary-Lou Tomson, Mark I Lorber, Youlan Rao, Meredith Broderick, Franck Rahaghi, Robert Naeije
Institutions: Rabin Medical Center, The University of Texas Southwestern Medical Center, University of Alabama at Birmingham, University of North Carolina at Chapel Hill, Albany Medical College, Brigham and Women's Hospital, Rex Hospital, University of California, Los Angeles, The Lundquist Institute, United Therapeutics (United States), Université Libre de Bruxelles
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,090
OpenAlex ID: W7164028567
